Understanding The Connections Between Aboriginal And Torres Strait Islander Culture, Health And Wellbeing To Support Action To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$1,915,802.00
Summary
Little is known about the inter-relationship of cultural factors and Aboriginal and Torres Strait Islander health outcomes and these relationships have not been quantified. Through a large cohort study, this research will produce data that combines standard health measures with newly developed quantitative measures of cultural factors, supported by data linkage infrastructure. Robust analytical methods will be used to inform policy and program development.
Predicting Renal, Ophthalmic, And Heart Events In The Aboriginal Community – THE PROPHECY Study
Funder
National Health and Medical Research Council
Funding Amount
$2,574,486.00
Summary
Up to 30% of adult Aboriginal people have diabetes yet our knowledge of the causes and predictors of complications remain incomplete. We have established the PROPHECY Study to assess the levels of complications in Aboriginal people with diabetes; to understand the way that these complications occur, and identify what clinical, social and genetic factors could predict who will get those complications to guide clinical management and prevention.
Clinical Review Of A Cohort Aged 22-33 Years Conceived Using Assisted Reproductive Technologies
Funder
National Health and Medical Research Council
Funding Amount
$946,454.00
Summary
In a recent study, using telephone-interviews, we compared the health and wellbeing of 547 singleton young adults born following assisted reproductive technologies (ART), with 549 matched controls. Reviewing their health when they are 22-33 years is possible because of their ongoing interest. We have a protocol in place to measure their cardiac and respiratory function and other aspects of growth and development. Our findings will fill a major knowledge gap about the longer term safety of ART.
Testosterone Intervention For The Prevention Of Diabetes Mellitus In High Risk Men: A Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$5,054,654.00
Summary
Type 2 diabetes (T2DM) is increasingly common, costly and deadly. Some men at risk of T2DM have low testosterone (T) levels. Our preliminary data suggests that T treatment may prevent the development of T2DM, and improve cardiovascular and sexual function, body composition and bone density, and mood. This remains to be fully tested in a randomized placebo-controlled trial, and this project will do so in a 2-year study of T treatment compared to placebo in men at risk of T2DM participating in a l ....Type 2 diabetes (T2DM) is increasingly common, costly and deadly. Some men at risk of T2DM have low testosterone (T) levels. Our preliminary data suggests that T treatment may prevent the development of T2DM, and improve cardiovascular and sexual function, body composition and bone density, and mood. This remains to be fully tested in a randomized placebo-controlled trial, and this project will do so in a 2-year study of T treatment compared to placebo in men at risk of T2DM participating in a lifestyle program.Read moreRead less
Reducing The Greatest Uncertainty In Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$594,197.00
Summary
The weakest link in radiotherapy is defining treatment volumes (contouring). Lack of accuracy and consistency in clinical trial contouring has been shown to result in reduced patient outcomes. Manual review of contouring is resource intensive, expensive and for advanced treatments unachievable in a timely fashion. We will assess an automated approach to contouring assessment using 4 clinical trial datasets, changing practice for future studies and enabling consistent assessment in the clinic.
The Treatment Of BOoking Gestational Diabetes Mellitus Study: The TOBOGM Study
Funder
National Health and Medical Research Council
Funding Amount
$2,197,280.00
Summary
Gestational diabetes mellitus (GDM) related pregnancy complications are reduced with treatment from 24-28 weeks pregnant. Many women are diagnosed/treated earlier without evidence of benefit and possible risk of harm. In TOBOGM women under 20 weeks pregnant with mildly raised blood glucose will be allocated by chance to either immediate treatment, or awaiting a repeat diabetes test at 24-28 weeks pregnant to decide treatment. Harmful and beneficial effects on mother and baby will be compared.